{"doi":"10.1016/j.jtho.2022.04.012","title":"Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC","abstract":null,"journal":"Journal of Thoracic Oncology","year":2022,"id":651663,"datarank":0.6515708132780527,"base_score":4.343805421853684,"endowment":4.343805421853684,"self_citation_contribution":0.6515708132780527,"citation_network_contribution":0.0,"self_endowment_contribution":0.6515708132780527,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":76,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1013872,"name":"Wei Guo","orcid":"0000-0001-5294-5047","position":1,"is_corresponding":false},{"id":1699642,"name":"Bolun Zhou","orcid":null,"position":2,"is_corresponding":false},{"id":533617,"name":"Shuhang Wang","orcid":"0000-0002-9386-4232","position":3,"is_corresponding":false},{"id":434621,"name":"Ning Li","orcid":"0000-0001-5997-5556","position":4,"is_corresponding":false},{"id":54714,"name":"Bin Qiu","orcid":"0000-0001-9161-1533","position":5,"is_corresponding":false},{"id":1699645,"name":"Fang Lv","orcid":null,"position":6,"is_corresponding":false},{"id":1109002,"name":"Liang Zhao","orcid":"0009-0002-7034-4231","position":7,"is_corresponding":false},{"id":407505,"name":"Jian Li","orcid":"0000-0002-7532-1728","position":8,"is_corresponding":false},{"id":583442,"name":"Kang Shao","orcid":"0000-0001-5779-8840","position":9,"is_corresponding":false},{"id":1485483,"name":"Qi Xue","orcid":"0000-0003-0562-9265","position":10,"is_corresponding":false},{"id":1013705,"name":"Shugeng Gao","orcid":"0000-0003-4211-552X","position":11,"is_corresponding":false},{"id":1464646,"name":"Jie He","orcid":"0000-0002-7136-4181","position":12,"is_corresponding":false},{"id":1338636,"name":"Fan Zhang","orcid":"0009-0006-6245-0199","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC","abstract":"INTRODUCTION: Programmed cell death protein-1 (PD-1) inhibitors have been proved to be feasible and to have efficacy in multiple cancers, including NSCLC. But few studies have evaluated the effectiveness of PD-1 inhibitor as neoadjuvant therapy with a long-term follow-up. Here, in this phase 1b study with a 3-year follow-up, we reported the clinical outcomes of patients who received the PD-1 inhibitor as neoadjuvant therapy. METHODS: Two doses of sintilimab (intravenously, 200 mg) were used for patients with stages IA to IIIB NSCLC (registration number: ChiCTR-OIC-17013726). Then, surgery was performed within 29 to 43 days after the first dose. All patients underwent positron emission tomography-computed tomography at enrolment and before surgery to evaluate tumor metabolism after administration of PD-1 inhibitor. We also evaluated the expression of programmed death-ligand 1 (PD-L1) as an exploratory analysis in 32 eligible patients. Safety was the primary end point. Overall survival (OS), disease-free survival (DFS), event-free survival, and major pathologic response were the key secondary end points. RESULTS: With the mean follow-up of 37.8 months, 3-year OS rate was 88.5% and the 3-year DFS rate was 75.0% among patients who underwent R0 resection. In patients with positive PD-L1 expression, 3-year OS and DFS rates were 95.5% and 81.8%, respectively. Eight patients had recurrent tumors, including local recurrence, lung metastasis, brain metastasis, and bone metastasis. Patients with PD-L1 greater than or equal to 1% had more favorable clinical outcomes than the other subgroup (hazard ratio = 0.275, 95% confidence interval: 0.078-0.976). No more new adverse events have occurred in the 3-year follow-up because we first reported them in the former publication. CONCLUSIONS: This is the first study to report the long-term survival probability of patients with NSCLC receiving PD-1 inhibitors as the neoadjuvant treatment. The 3-year follow-up results revealed that patients with positive PD-L1 expression and high tumor mutation burden have favorable clinical outcomes.","is_dataset_classified":null,"base_score":4.343805421853684,"endowment":4.343805421853684,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35550174","pmcid":null,"openalex_id":"https://openalex.org/W4229441266","authors":[],"funders":[{"funder_name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","grant_id":"2021-1-I2M-015","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"82002451","title":null},{"funder_name":"Peking Union Medical College Hospital","grant_id":"3332020024","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"","title":null}],"total_grants":4,"fwci":6.7885,"citation_percentile":0.97994752,"influential_citations":0,"citation_trend":[{"year":2022,"count":4},{"year":2023,"count":31},{"year":2024,"count":27},{"year":2025,"count":11},{"year":2026,"count":3}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"http://www.jto.org/article/S1556086422002167/pdf","host_type":"journal"},{"url":"http://www.jto.org/article/S1556086422002167/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1556086422002167?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1556086422002167?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jtho.2022.04.012","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35550174","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Colorectal and Anal Carcinomas","Pancreatic and Hepatic Oncology Research","Antibodies, Monoclonal, Humanized","Apoptosis Regulatory Proteins","B7-H1 Antigen","Carcinoma, Non-Small-Cell Lung","Follow-Up Studies","Humans","Immune Checkpoint Inhibitors","Lung Neoplasms","Neoadjuvant Therapy"],"mesh_terms":["Immune Checkpoint Inhibitors","Carcinoma, Non-Small-Cell Lung","Follow-Up Studies","Humans","Lung Neoplasms","Neoadjuvant Therapy","Apoptosis Regulatory Proteins","B7-H1 Antigen","Antibodies, Monoclonal, Humanized"],"keywords":["Medicine","Programmed cell death 1","Oncology","Neoadjuvant therapy","Internal medicine","Cancer","PD-L1","Immunotherapy","TMB","NSCLC","Neoadjuvant","Pd-1 Inhibitor","Pd-l1 Expression"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T10:18:02.961594Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}